Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results
Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective
Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia
Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM
Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies
The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL
Key insights from lung cancer research at ASCO 2025
POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma
ASCO 2025: Importance of early testing in metastatic prostate cancer
Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer
ctDNA-guided chemo escalation does not improve recurrence-free survival in stage III colon cancer
Disparities in mammogram screening amongst LGBTQ+ populations